Haleon PLC Sponsored ADR $HLN Stock Holdings Lifted by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 4.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 31,423 shares of the company’s stock after buying an additional 1,200 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Haleon were worth $321,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Acadian Asset Management LLC bought a new position in shares of Haleon in the first quarter valued at $1,767,000. Arlington Partners LLC bought a new position in shares of Haleon in the second quarter valued at $2,315,000. Oppenheimer & Co. Inc. increased its holdings in shares of Haleon by 11.2% in the first quarter. Oppenheimer & Co. Inc. now owns 25,362 shares of the company’s stock valued at $261,000 after buying an additional 2,564 shares in the last quarter. Concurrent Investment Advisors LLC increased its holdings in shares of Haleon by 32.9% in the first quarter. Concurrent Investment Advisors LLC now owns 16,363 shares of the company’s stock valued at $168,000 after buying an additional 4,055 shares in the last quarter. Finally, Mather Group LLC. increased its holdings in shares of Haleon by 60.7% in the first quarter. Mather Group LLC. now owns 9,036 shares of the company’s stock valued at $93,000 after buying an additional 3,413 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. The Goldman Sachs Group raised Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research note on Saturday. Barclays downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, September 16th. Finally, Wall Street Zen downgraded shares of Haleon from a “buy” rating to a “hold” rating in a research note on Saturday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Haleon presently has an average rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Trading Down 1.3%

NYSE HLN opened at $9.25 on Friday. Haleon PLC Sponsored ADR has a 1-year low of $8.71 and a 1-year high of $11.42. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $41.17 billion, a PE ratio of 23.71, a price-to-earnings-growth ratio of 2.70 and a beta of 0.20. The firm’s fifty day simple moving average is $9.38 and its 200-day simple moving average is $9.98.

Haleon Increases Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Thursday, September 18th. Investors of record on Friday, August 15th were issued a $0.0555 dividend. This is a boost from Haleon’s previous semi-annual dividend of $0.05. This represents a yield of 190.0%. The ex-dividend date was Friday, August 15th. Haleon’s dividend payout ratio is currently 28.21%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.